Matrix metalloproteinases and TIMPs: Properties and implications for the rheumatic diseases

Molecular Medicine Today

Volumn 4, Issue 3, 1998, Pages 130-137

  Cawston, Tim ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE;

CARTILAGE MATRIX; ENZYME ACTIVATION; HUMAN; OSTEOARTHRITIS; PROTEIN DEGRADATION; REVIEW; RHEUMATIC DISEASE; TRIPLE HELIX;

ANIMALIA;

EID: 0031978254     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(97)01192-1     Document Type: Review

References (42)

1. Prockop D.J., Kivirikko K.I. Collagens: molecular biology, diseases, and potentials for therapy. Annu. Rev. Biochem. 64:1995;403-434.
2. Hardingham T.E., Fosang A.J. Proteoglycans: many forms and functions. FASEB J. 6:1992;861-870.
3. Barrett A.J. Classification of peptidases. Methods Enzymol. 244:1994;1-15.
4. Cawston T.E. Metalloproteinase inhibitors. Pharmacol. Ther. 70:1996;163-182.
5. Weyand C.M., Goronzy J.J. Pathogenesis of rheumatoid arthritis. Med. Clin. North Am. 81:1997;29-55.
6. Creamer P., Hochberg M.C. Osteoarthritis. Lancet. 350:1997;503-509.
7. Woessner J. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 5:1991;2145-2154.
8. Birkedal-Hansen H.et al. Matrix metalloproteinases: a review. Crit. Rev. Oral Biol. Med. 4:1993;197-250.
9. Murphy G., Knauper V. Relating matrix metalloproteinase structure to function: why the 'hemopexin' domain? Matrix Biol. 15:1997;511-518.
10. Goldring, M.B. (1993) Degradation of articular cartilage in culture: regulatory factors, in Joint Cartilage Degradation (Woessner, J.F. and Howell, D.S., eds), Marcel Dekker, pp. 281-346.
11. Shingleton W.D., Hodges D.J., Brick P., Cawston T.E. Collagenase: a key enzyme in collagen turnover. Biochem. Cell Biol. 74:1996;759-775.
12. Vincenti M.P., Clark I.M., Brinckherhoff C.E. Using inhibitors of metalloproteinases to treat arthritis: easier said than done. Arthritis Rheum. 37:1994;1115-1126.
13. MacNaul K.L.et al. Discoordinate expression of stromelysin, collagenase and TIMP in human rheumatoid synovial fibroblasts: synergistic effects of IL-1 and TNF on stromelysin expression. J. Biol. Chem. 265:1990;17238-17245.
14. Clark I.M., Powell L.K., Hazleman B.L., Cawston T.E. The measurement of collagenase, TIMP and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum. 36:1993;372-379.
15. Brinkerhoff C.E. Joint destruction in arthritis: metalloproteinases in the spotlight. Arthritis Rheum. 34:1991;1073-1075.
16. Wolfe G.C.et al. Differential in vivo expression of collagenase messenger RNA in synovium and cartilage: quantitative comparison with stromelysin messenger RNA levels in human rheumatoid arthritis and osteoarthritis patients and in two animal models of acute inflammatory arthritis. Arthritis Rheum. 36:1993;1540-1547.
17. Ellis A.J., Curry V.A., Powell E.K., Cawston T.E. The prevention of collagen breakdown in bovine nasal cartilage by TIMP, TIMP-2 and a low molecular weight synthetic inhibitor. Biochem. Biophys. Res. Commun. 201:1994;94-101.
18. Hill P.A.et al. The effects of selective inhibitors of matrix metalloproteinases (MMPs) on bone resorption and the identification of MMPs and TIMP-1 in isolated osteoclasts. J. Cell Sci. 107:1994;3055-3064.
19. Sandy J.D., Flannery C.R., Neame P.J., Lohmander L.S. The structure of aggrecan fragments in human synovial fluid: evidence for the involvement in osteoarthritis of a novel proteinase. J. Clin. Invest. 89:1992;1512-1516.
20. Moss M.L.et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α Nature. 385:1997;733-736.
21. Wolfsberg T.G., Primakoff P., Myles D.G., White J.M. ADAM, a novel family of membrane proteins containing a disintegrin and metalloprotease domain: multipotential functions in cell-cell and cell-matrix interactions. J. Cell Biol. 131:1995;275-278.
22. Springman E.B., Angleton E.L., Birkedal-Hansen H., van Wart H.E. Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a 'cysteine switch' mechanism for activation. Proc. Natl. Acad. Sci. U. S. A. 87:1990;364-368.
23. Van Roon J.A.G.et al. Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. Arthritis Rheum. 39:1996;829-835.
24. Cawston T.E.et al. Interleukin-1 and oncostatin M in combination promote the release of collagen fragments from bovine nasal cartilage in culture. Biochem. Biophys. Res. Commun. 215:1995;377-385.
25. Korzus E., Nagase H., Rydell R., Travis J. The mitogen-activated protein kinase and JAK-STAT signaling pathways are required for an oncostatin M-responsive element-mediated activation of matrix metalloproteinase 1 gene expression. J. Biol. Chem. 272:1997;1118-1196.
26. Pei D., Weiss S.J. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature. 375:1995;244-247.
27. Murphy G.et al. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann. New York Acad. Sci. 667:1992;1-12.
28. Saari H.et al. Activation of latent human neutrophil collagenase by reactive oxygen species and serine proteases. Biochem. Biophys. Res. Commun. 171:1990;979-987.
29. Murphy G., Willenbrock F. Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol. 248:1995;496-510.
30. Denhardt D.T.et al. Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol. Ther. 59:1993;329-341.
31. Gomis-Ruth F-X.et al. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature. 389:1997;77-80.
32. Hayakawa H., Yamashita K., Ohuchi E., Shingawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J. Cell Sci. 107:1994;2373-2379.
33. Buttle D.J., Bramwell H., Hollander A.P. Proteolytic mechanisms of cartilage breakdown: a target for arthritis therapy? J. Clin. Pathol. 48:1995;M167-M177.
34. Modu V.et al. Oncostatin M is a proinflammatory mediator: in vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. J. Clin. Invest. 100:1997;158-168.
35. Cawston T.E.et al. Interleukin-4 blocks the release of collagen fragments from bovine nasal cartilage treated with cytokines. Biochim. Biophys. Acta. 1314:1996;226-232.
36. Porter J.R.et al. Potent and selective inhibitors of gelatinase-A. 1. Hydroxamic acid derivatives. Bioorg. Med. Chem. Lett. 4:1994;2741-2746.
37. Beckett R.P.et al. Recent advances in matrix metalloproteinase inhibitor research. Drug Discovery Today. 1:1996;16-26.
38. Karran E.H., Young T.J., Markwell R.E., Harper G.P. In vivo model of cartilage degradation - effects of a matrix metalloproteinase inhibitor. Ann. Rheum. Dis. 54:1995;662-669.
39. Li J.et al. Structure of full-length porcine synovial collagenase reveals a C-terminal domain containing a calcium-linked, four-bladed β-propeller. Structure. 3:1995;541-549.
40. Tschesche H.et al. Function and structure of human leucocyte collagenase. J. Protein Chem. 13:1994;460-461.
41. Greenwald R., Moak S.A., Ramumurthy N.S., Golub L.M. Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage. J. Rheumatol. 19:1992;927-938.
42. Greenwald R.A. Treatment of destructive arthritic disorders with MMP inhibitors. Potential role of tetracyclines. Ann. New York Acad. Sci. 732:1994;181-198.